Future opportunities for the diagnosis and treatment of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue , 2004, Pages S8-S13

  Watson, R W G ^a   Schalken, J A ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biological markers; Diagnosis; Genetic markers; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER VACCINE; GENOMIC DNA; GONADORELIN DERIVATIVE; GROWTH FACTOR; KALLIKREIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUJ591; NERVE CELL ADHESION MOLECULE; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RESEARCH; CANCER STAGING; CANCER THERAPY; CASTRATION; CELL INTERACTION; CLINICAL TRIAL; DIAGNOSTIC TEST; DIGITAL RECTAL EXAMINATION; DNA MICROARRAY; DRUG TARGETING; EPITHELIUM CELL; EXPERIMENTAL DESIGN; FUTUROLOGY; GENE THERAPY; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOREGULATION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEOMICS; STROMA CELL; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT PLANNING; VALIDATION PROCESS; MALE; MORTALITY; PROSTATE TUMOR; REVIEW; SURVIVAL;

CLINICAL TRIALS; GENE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; SURVIVAL;

EID: 16544362158     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500742     Document Type: Article

References (39)

1. Huggins C, Hodges C. Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
2. Aus G et al. EAU guidelines on prostate cancer. Eur Urol 2001; 40: 97-101.
3. Thompson I, Leach RJ, Pollock BH, Naylor SL. Prostate cancer and prostate-specific antigen: the more we know, the less we understand. J Natl Cancer Inst 2003; 95: 1027-1028.
4. Cramer SD et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostatespecific antigen levels. J Natl Cancer Inst 2003; 95: 1044-1053.
5. Galic J et al. Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer. Coll Antropol 2003; 27 (Suppl 1): 61-66.
6. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64.
7. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361: 955-964.
8. Allsbrook Jr WC et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001; 32: 74-80.
9. Allsbrook Jr WC et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001; 32: 81-88.
10. Corcoran NM, Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91: 545-553.
11. Bello-DeOcampo D, Tindall DJ. TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets 2003; 4: 197-207.
12. Wikstrom P et al. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37: 19-29.
13. Tavtigian SV et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27: 172-180.
14. Korver W et al. The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex. Int J Cancer 2003; 104: 283-288.
15. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-1992.
16. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-1365.
17. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-1316.
18. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003; 62 (5 Suppl 1): 34-43.
19. Fradet Y et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; in press.
20. Watson RW. Gene-chip technology and prostate cancer: the identification of new genes regulating tumour progression. BJU Int 2003; 91: 307.
21. Ahram M et al. Proteomic analysis of human prostate cancer. Mol Carcinogen 2002; 33: 9-15.
22. Chakrabarti R, Robles LD, Gibson J, Muroski M. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines. Cancer Genet Cytogenet 2002; 139: 115-125.
23. Luo J et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002; 62: 2220-2226.
24. Varambally S et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
25. Petricoin III EF et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-1578.
26. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology 2003; 62 (5 Suppl 1): 11-20.
27. Nicholson B, Theodorescu D. Molecular therapeutics in prostate cancer. Histol Histopathol 2003; 18: 275-298.
28. Hudes GR. Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs 2002; 20: 159-172.
29. Steiner MS, Gingrich JR, Chauhan RD. Prostate cancer gene therapy. Surg Oncol Clin N Am 2002; 11: 607-620.
30. Chung LW et al. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. Urology 2003; 62 (5 Suppl 1): 44-54.
31. Umbas R et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 3929-3933.
32. Tomita K. Cell Adhesion Molecules in Bladder and Prostate Cancer. University of Nijmegen: Nijmegen, 2004.
33. Cavallaro U, Schaffhauser B, Christofori G. Cadherins and the tumour progression: is it all in a switch? Cancer Lett 2002; 176: 123-128.
34. Borgstrom P et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998; 35: 1-10.
35. Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003; 4: 123-131.
36. Brooks PC et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
37. Horig H, Lee CS, Kaufman HL. Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther 2002; 2: 395-408.
38. Nanus DM et al. Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J Urol 2003; 170: S84-S89.
39. Morris MJ, Scher HI. Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surg Oncol 2002; 11: 13-23.